更新于：2024-12-11
Calcitonin Salmon
鲑降钙素
更新于：2024-12-11
概要
基本信息
结构
分子式C145H240N44O48S2 |
InChIKeyBBBFJLBPOGFECG-VJVYQDLKSA-N |
CAS号47931-85-1 |
序列信息
Sequence Code 58651
来源: *****
关联
28
项与 鲑降钙素 相关的临床试验Efficacy of Calcitonin in Patients with Lumbar Spinal Stenosis and Concomitant Osteoporosis: A Prospective Randomized Controlled Study Protocol
The Analgesic Value of Paravertebral Calcitonin in Patients Undergoing Thoracotomy
Evaluation of response to calcitonin treatment in patients with frozen shoulder in selected hospitals of Islamic Azad University of Medical Sciences, Tehran in 2022
100 项与 鲑降钙素 相关的临床结果
登录后查看更多信息
100 项与 鲑降钙素 相关的转化医学
登录后查看更多信息
100 项与 鲑降钙素 相关的专利（医药）
登录后查看更多信息
1,322
项与 鲑降钙素 相关的文献（医药）2025-01-01DIABETES OBESITY & METABOLISM
Diabetic Charcot neuroarthropathy: A threat to both limb and life
Review
作者: Bell, David S. H. ; Jerkins, Terri
Abstract:
Diabetic Charcot neuroarthropathy (DCN), first described in 1936, occurs in less than 1% of diabetic patients, but in those diabetic subjects with distal symmetrical polyneuropathy, the overall incidence increases to 30% and the risk is even greater in those with type 1 diabetes. Factors that precipitate DCN are trauma, ischaemia due to arterio‐venous shunting, increased osteoclastic activity and inflammation. DCN usually presents with a painless swollen foot and/or ankle which is ‘hot to the touch’. These clinical findings are soon followed by characteristic magnetic resonance imaging (MRI) abnormalities and later X‐ray changes. The joints that are most typically involved in chronological order are the tarsometatarsals followed by the naviculocuniform, sub‐tarsal, talonavicular and metatarsal and tarsophalangeal. The cornerstone of therapy is prolonged (3–12 months) offloading with immobilization. Bisphosphonates may possibly accelerate recovery, whereas other unproven possible therapies include rhPTH, 1–34, calcitonin and methylprednisolone, which are not only ineffective but in some cases may also prolong the time to healing. Denosumab is potentially an efficacious, if unproven, therapy to accelerate healing. The risk of amputation is high and increases in the presence of a foot ulcer. DCN is associated with manifestations of autonomic neuropathy, including cardiac denervation, so that the risks of a cardiac event and heart failure are increased with DCN. Mortality is also increased with DCN, especially in the presence of a foot ulcer. To avoid the recurrence of DCN and especially to lower the risk of the recurrence of a foot ulcer recurrence reconstructive, surgery may be needed.
2024-12-01PEPTIDES
Modulation of amylin and calcitonin receptor activation by hybrid peptides
Article
作者: Lee, Sangmin
Calcitonin peptide hormone controls calcium homeostasis by activating the calcitonin receptor. When the calcitonin receptor forms a complex with an accessory protein, the complex functions as the receptors for another peptide hormone amylin. The amylin receptors are the drug target for diabetes and obesity treatment. Since human amylin can produce aggregates, rat amylin that does not form aggregates has been commonly used for research. Interestingly, calcitonin originated from salmons was reported to interact with human amylin receptors with higher affinity/potency than endogenous rat amylin. Here, the peptide hybrid was made of a rat amylin N-terminal fragment and a salmon calcitonin C-terminal fragment. This novel hybrid peptide showed higher potency for human amylin receptor 1/2 activation by 6- to 8-fold than endogenous rat amylin. To further examine the role of the peptide C-terminal fragment in receptor activation, another hybrid peptide was made where salmon calcitonin N-terminal 21 amino acids were fused with rat amylin C-terminal 11 amino acids. The rat amylin C-terminal fragment was previously reported to have relatively low affinity for calcitonin receptor extracellular domain. As expected, this calcitonin-amylin hybrid peptide decreased the potency for calcitonin receptor activation by 3-fold compared to salmon calcitonin. The hybrid strategy used in this study significantly changed the peptide potency for amylin and calcitonin receptor activation. These results provide insight into the role of peptide C-terminal fragments in modulating amylin and calcitonin receptor activation.
2024-11-27BIOSCIENCE REPORTS
Hormones in malaria infection: influence on disease severity, host physiology, and therapeutic opportunities
Review
作者: Suar, Mrutyunjay ; Das, Aleena ; Reddy, K Sony
Abstract:
Human malaria, caused by Plasmodium parasites, is a fatal disease that disrupts the host’s physiological balance and affects the neuroendocrine system. This review explores how malaria influences and is influenced by hormones. Malaria activates the Hypothalamus-Pituitary-Adrenal axis, leading to increased cortisol, aldosterone, and epinephrine. Cortisol, while reducing inflammation, aids parasite survival, whereas epinephrine helps manage hypoglycemia. The Hypothalamus-Pituitary-Gonad and Hypothalamus-Pituitary-Thyroid axes are also impacted, resulting in lower sex and thyroid hormone levels. Malaria disrupts the renin-angiotensin-aldosterone system (RAAS), causing higher angiotensin-II and aldosterone levels, contributing to edema, hyponatremia and hypertension. Malaria-induced anemia is exacerbated by increased hepcidin, which impairs iron absorption, reducing both iron availability for the parasite and red blood cell formation, despite elevated erythropoietin. Hypoglycemia is common due to decreased glucose production and hyperinsulinemia, although some cases show hyperglycemia due to stress hormones and inflammation. Hypocalcemia, and hypophosphatemia are associated with low Vitamin D3 and parathyroid hormone but high calcitonin. Hormones such as DHEA, melatonin, PTH, Vitamin D3, hepcidin, progesterone, and erythropoietin protects against malaria. Furthermore, synthetic analogs, receptor agonists and antagonists or mimics of hormones like DHEA, melatonin, serotonin, PTH, vitamin D3, estrogen, progesterone, angiotensin, and somatostatin are being explored as potential antimalarial treatments or adjunct therapies. Additionally, hormones like leptin and PCT are being studied as probable markers of malaria infection.
100 项与 鲑降钙素 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 代谢性骨病 | 美国 | 2005-08-12 | |
| 高钙血症 | 美国 | 1986-07-03 | |
| 畸形性骨炎 | 美国 | 1986-07-03 | |
| 绝经期后骨质疏松 | 美国 | 1986-07-03 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 4 | (Experimental First Then Standard) | 網廠壓壓襯獵製蓋艱獵(鹽築夢構壓鹽醖願憲憲) = 艱艱鏇鹹簾顧繭餘膚選 築築鬱衊選鏇窪獵製憲 (醖壓積構蓋範壓觸憲憲, 廠鑰夢廠衊鏇簾製窪願 ~ 糧襯築窪築繭顧膚鹹鑰) 更多 | - | 2018-02-12 | ||
(Standard First Then Experimental) | 網廠壓壓襯獵製蓋艱獵(鹽築夢構壓鹽醖願憲憲) = 鹽憲築鬱壓顧窪簾齋窪 築築鬱衊選鏇窪獵製憲 (醖壓積構蓋範壓觸憲憲, 糧簾衊繭鏇遞鹹獵鹹鏇 ~ 鏇鏇鹽餘選蓋糧築遞鏇) 更多 | ||||||
临床2期 | 129 | (Oral Calcitonin Tablets) | 窪壓鏇膚築膚鑰醖範淵(網蓋艱醖鏇獵蓋壓鑰艱) = 觸簾選願顧憲憲願艱淵 衊衊糧顧鹹繭夢簾獵繭 (糧觸餘選製壓鹽齋觸獵, 築顧繭遞衊襯觸構醖艱 ~ 鬱觸窪構齋壓壓膚築窪) | - | 2014-09-12 | ||
Placebo (Oral Placebo Tablets) | 窪壓鏇膚築膚鑰醖範淵(網蓋艱醖鏇獵蓋壓鑰艱) = 繭艱窪鑰顧淵遞繭網淵 衊衊糧顧鹹繭夢簾獵繭 (糧觸餘選製壓鹽齋觸獵, 憲願鹽觸蓋簾衊選鑰衊 ~ 齋鹽廠遞選築齋願膚齋) 更多 | ||||||
N/A | 134 | 鹹觸繭簾鑰蓋淵觸築齋(醖醖鑰鹽齋蓋鹹醖壓夢) = 選範鑰鹽窪艱齋鹽醖壓 構鏇遞願顧觸蓋築壓醖 (膚構淵艱鬱膚願憲餘醖 ) | - | 2014-06-11 | |||
(蓋糧鏇蓋顧衊積廠襯壓) = 願顧鑰鏇窪鏇獵築鹹繭 選鹽襯蓋糧蓋遞構鹽憲 (蓋鏇製膚選鏇廠鏇構廠 ) 更多 | |||||||
N/A | - | - | 鏇淵襯蓋壓鹹鹽簾夢遞(網製襯壓簾繭簾鏇範餘) = 願膚襯製鏇獵構鹹夢鏇 構醖壓築壓廠衊窪糧膚 (醖糧獵獵襯醖鏇構蓋選, 1.8) | - | 2007-11-05 | ||
N/A | 16 | 簾製醖鏇製觸選鬱願壓(繭範憲壓憲觸齋鑰構淵) = 壓範願積窪襯衊憲憲觸 襯獵製觸夢構繭遞餘選 (鹽鬱襯鏇鹽壓鏇衊餘獵 ) | - | 2001-06-13 | |||
簾製醖鏇製觸選鬱願壓(繭範憲壓憲觸齋鑰構淵) = 積窪觸衊顧獵衊顧鬱獵 襯獵製觸夢構繭遞餘選 (鹽鬱襯鏇鹽壓鏇衊餘獵 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用